Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated a biopharmaceutical company focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone a captisol-enabled formulation of amiodarone; and Zulresso a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition it provides Noxafil-IV a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances licenses and other business relationships with Amgen Merck Pfizer Jazz Takeda Gilead Sciences and Baxter International. Further it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego California.